1624607-04-0

Basic information

• Product Name: 5-((4-methoxybenzyl)oxy)-3-methyl-2-vinylpyridine
• Synonyms: 5-((4-methoxybenzyl)oxy)-3-methyl-2-vinylpyridine
• CAS NO: 1624607-04-0
• Molecular Weight: 255.316
• Mol File: 1624607-04-0.mol

Chemical Properties

• CAS DataBase Reference: 5-((4-methoxybenzyl)oxy)-3-methyl-2-vinylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((4-methoxybenzyl)oxy)-3-methyl-2-vinylpyridine(1624607-04-0)
• EPA Substance Registry System: 5-((4-methoxybenzyl)oxy)-3-methyl-2-vinylpyridine(1624607-04-0)

Safety Data

• Hazardous Substances Data: 1624607-04-0(Hazardous Substances Data)

Upstream product

• 1315360-83-8 2-chloro-5-(difluoromethoxy)-3-methylpyridine 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 38186-82-2 6-chloro-5-methylpyridin-3-amine 
• 22280-56-4 2-chloro-3-methyl-5-nitropyridine 
• 54232-04-1 6-chloro-5-methylpyridine-3-yl acetate 
• 54232-03-0 2-chloro-5-hydroxy-3-methylpyridine 
• 1624607-03-9 2-chloro-5-((4-methoxybenzyl)oxy)-3-methylpyridine 

Relevant articles and documents

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.